Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SZR001
MIFTS: 66

Sezary's Disease

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Sezary's Disease

About this section

MalaCards integrated aliases for Sezary's Disease:

Name: Sezary's Disease 12 15 17
Sezary Syndrome 12 77 54 26 56 6 45 74
Sézary Syndrome 54 26 60
Sezary's Lymphoma 54 26
Sezary Erythroderma 26
Sézary Lymphoma 60
Sezary Disease 12

Characteristics:

Orphanet epidemiological data:

60
sézary syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: <1/1000000 (United States),<1/1000000 (Norway); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Skin diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare skin diseases
Rare haematological diseases


Sources

Summaries for Sezary's Disease

About this section
NIH Rare Diseases : 54 Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes. Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma; malformation of the nails; and hepatosplenomegaly. The exact cause of Sezary syndrome is currently unknown. Treatment varies based on the signs and symptoms present in each person and the severity of the condition.

MalaCards based summary : Sezary's Disease, also known as sezary syndrome, is related to hematopoietic stem cell transplantation and cutaneous t cell lymphoma, and has symptoms including pruritus An important gene associated with Sezary's Disease is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Denileukin diftitox and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone marrow, and related phenotypes are pruritus and dry skin

Genetics Home Reference : 26 Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform.

Wikipedia : 77 Sézary disease is a type of cutaneous lymphoma that was first described by Albert Sézary. The affected... more...

Sources

Related Diseases for Sezary's Disease

About this section

Diseases related to Sezary's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 30.9 CTLA4 IFNG IL2
2 cutaneous t cell lymphoma 30.9 IFNG IL2 IL2RA IL4 IL7
3 dermatitis, atopic 30.8 IFNG IL2 IL4 IL5
4 leukemia, chronic lymphocytic 30.6 BCL10 IL2 IL2RA IL4 IL7
5 cutaneous leishmaniasis 30.6 IFNG IL4 IL5
6 leishmaniasis 30.6 IFNG IL4 IL5
7 uveitis 30.5 CTLA4 IFNG IL2RA IL4
8 human immunodeficiency virus infectious disease 30.4 IFNG IL2 IL7
9 acquired immunodeficiency syndrome 30.3 IFNG IL2 IL2RA
10 folliculitis 30.3 IFNG IL2RA IL4 IL5
11 mycosis fungoides 30.1 CCR10 CD28 CTLA4 DPP4 IL2 IL2RA
12 exanthem 10.5 CTLA4 IL2 TNFRSF1B
13 virus associated hemophagocytic syndrome 10.5 IL2 IL4
14 chronic active epstein-barr virus infection 10.5 CTLA4 IFNG IL2
15 variola major 10.5 IFNG IL2
16 rheumatoid factor-negative juvenile idiopathic arthritis 10.5 IL2RA STAT4
17 eosinophilic fasciitis 10.5 IFNG IL5
18 lymphoma 10.5
19 cephalosporin allergy 10.5 IFNG IL5
20 angiostrongyliasis 10.5 IL2 IL4 IL5
21 autoimmune disease of endocrine system 10.5 CTLA4 IFNG IL2
22 severe combined immunodeficiency, x-linked 10.5 IL2 IL4 IL7
23 gaucher disease, type ii 10.5 IL2 IL4 IL5
24 hyperlucent lung 10.5 IFNG IL2RA IL4
25 hypersensitivity reaction type iv disease 10.5 IFNG IL2 TNFRSF1B
26 b-cell growth factor 10.5 IFNG IL4 IL7
27 large granular lymphocyte leukemia 10.5 IFNG IL2RA
28 coccidiosis 10.5 IFNG IL2 IL4
29 intermediate uveitis 10.5 IFNG IL2 IL2RA
30 autoimmune vasculitis 10.5 IL2 IL4
31 posterior uveitis 10.5 IFNG IL2 IL2RA
32 autoimmune gastritis 10.5 IL2 IL4 KIR3DL2
33 wells syndrome 10.5 IL2 IL2RA IL5
34 pure red-cell aplasia 10.5 IL2 IL2RA TRB
35 onchocerciasis 10.5 IL2 IL4 IL5
36 nickel allergic contact dermatitis 10.5 IFNG IL4 IL5
37 allergic contact dermatitis 10.5 IFNG IL4 IL5
38 contact dermatitis 10.4 IFNG IL4 IL5
39 scleritis 10.4 IFNG IL4 IL5
40 parasitic helminthiasis infectious disease 10.4 IL2 IL4 IL5
41 autoimmune disease of musculoskeletal system 10.4 IL2 IL4 STAT4
42 autoimmune uveitis 10.4 IFNG IL2 IL4
43 fixed drug eruption 10.4 IFNG IL2
44 cat-scratch disease 10.4 IFNG TNFRSF1B
45 immune deficiency disease 10.4 IL2 IL2RA IL4
46 tonsillitis 10.4 IFNG IL2 IL4
47 tropical spastic paraparesis 10.4 IFNG IL2 IL2RA
48 stevens-johnson syndrome/toxic epidermal necrolysis 10.4 IFNG IL2 IL5
49 parasitic protozoa infectious disease 10.4 IFNG IL2 IL4
50 mumps 10.4 IFNG IL2 IL2RA

Graphical network of the top 20 diseases related to Sezary's Disease:



Diseases related to Sezary's Disease
Sources

Symptoms & Phenotypes for Sezary's Disease

About this section

Human phenotypes related to Sezary's Disease:

60 33 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 60 33 hallmark (90%) Very frequent (99-80%) HP:0000989
2 dry skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0000958
3 neoplasm of the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0008069
4 lymphadenopathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0002716
5 erythroderma 60 33 hallmark (90%) Very frequent (99-80%) HP:0001019
6 lichenification 60 33 hallmark (90%) Very frequent (99-80%) HP:0100725
7 cutaneous t-cell lymphoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0012192
8 abnormal lymphocyte morphology 33 hallmark (90%) HP:0004332
9 splenomegaly 60 33 frequent (33%) Frequent (79-30%) HP:0001744
10 hepatomegaly 60 33 frequent (33%) Frequent (79-30%) HP:0002240
11 immunodeficiency 60 33 frequent (33%) Frequent (79-30%) HP:0002721
12 palmoplantar keratoderma 60 33 frequent (33%) Frequent (79-30%) HP:0000982
13 nail dystrophy 60 33 frequent (33%) Frequent (79-30%) HP:0008404
14 alopecia 60 33 frequent (33%) Frequent (79-30%) HP:0001596
15 tremor 60 33 occasional (7.5%) Occasional (29-5%) HP:0001337
16 abnormal facial shape 60 33 occasional (7.5%) Occasional (29-5%) HP:0001999
17 skeletal muscle atrophy 60 33 occasional (7.5%) Occasional (29-5%) HP:0003202
18 edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0000969
19 peripheral neuropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0009830
20 abnormality of the pleura 60 33 occasional (7.5%) Occasional (29-5%) HP:0002103
21 irregular hyperpigmentation 60 33 occasional (7.5%) Occasional (29-5%) HP:0007400
22 abnormal immunoglobulin level 60 33 occasional (7.5%) Occasional (29-5%) HP:0010701
23 ectropion 60 33 occasional (7.5%) Occasional (29-5%) HP:0000656
24 gangrene 60 33 occasional (7.5%) Occasional (29-5%) HP:0100758
25 abnormality of the face 60 Frequent (79-30%)
26 lymphoma 60 Very frequent (99-80%)
27 abnormality of lymphocytes 60 Very frequent (99-80%)

UMLS symptoms related to Sezary's Disease:


pruritus

MGI Mouse Phenotypes related to Sezary's Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 BCL10 CCR10 CD28 CTLA4 DPP4 IFNG
2 hematopoietic system MP:0005397 10.1 BCL10 CCR10 CD28 CTLA4 IFNG IFNGR2
3 digestive/alimentary MP:0005381 9.97 CD28 CTLA4 IFNG IL2 IL2RA IL4
4 homeostasis/metabolism MP:0005376 9.93 CD28 CTLA4 DPP4 IFNG IFNGR2 IL2
5 immune system MP:0005387 9.8 BCL10 CCR10 CD28 CTLA4 IFNG IFNGR2
6 respiratory system MP:0005388 9.17 CTLA4 IFNG IL2 IL2RA IL4 IL5
Sources

Drugs & Therapeutics for Sezary's Disease

About this section

Drugs for Sezary's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Not Applicable 173146-27-5
2
Aprepitant Approved, Investigational Phase 4,Not Applicable 170729-80-3 6918365 151165
3
Fosaprepitant Approved Phase 4,Not Applicable 172673-20-0 219090
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Neurokinin-1 Receptor Antagonists Phase 4,Not Applicable
10
Substance P Phase 4,Not Applicable 33507-63-0 44359816
11 neurokinin A Phase 4,Not Applicable
12
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
13 Orange Approved Phase 3
14
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
15
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
16
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
17
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
18
Ofloxacin Approved Phase 3 82419-36-1 4583
19
Bexarotene Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 153559-49-0 82146
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
21
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
22
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
23
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
24
Methoxsalen Approved Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
25
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 23214-92-8 31703
26
Panobinostat Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 404950-80-7 6918837
27
Iron Approved, Experimental Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
28
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
32
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
33
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
34
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
35
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
36
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
37
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
38
Captopril Approved Phase 3 62571-86-2 44093
39
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
40
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
41
Acyclovir Approved Phase 3 59277-89-3 2022
42
Vorinostat Approved, Investigational Phase 3,Phase 2,Phase 1 149647-78-9 5311
43
Mogamulizumab Approved, Investigational Phase 3,Phase 2 1159266-37-1
44
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
45
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
46
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
47
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
48
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 53-03-2 5865
49
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
50
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596

Interventional clinical trials:

(show top 50) (show all 349)
# Name Status NCT ID Phase Drugs
1 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
2 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
3 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4 Aprepitant;Placebo
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
6 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
7 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3 Panobinostat
8 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3 LBH589
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
17 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
18 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
19 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
20 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
21 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
22 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
23 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
24 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
25 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Recruiting NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
26 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Active, not recruiting NCT01728805 Phase 3 Vorinostat
27 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
28 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
29 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3 lenalidomide
30 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
31 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
32 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
33 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3 bortezomib;vorinostat
34 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
35 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
36 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
37 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2 bexarotene;methoxsalen
38 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
39 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
40 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
41 Immunization Against Tumor Cells in Sezary Syndrome Completed NCT00099593 Phase 2
42 Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome Completed NCT00057967 Phase 2
43 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome Completed NCT00047060 Phase 1, Phase 2 cyclosporine;fludarabine;Campath
44 Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
45 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
46 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma Completed NCT00255801 Phase 2 Targretin® (bexarotene);pegylated liposomal doxorubicin hydrochloride
47 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
48 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine
49 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
50 Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

Search NIH Clinical Center for Sezary's Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: sezary syndrome

Sources

Genetic Tests for Sezary's Disease

About this section
Sources

Anatomical Context for Sezary's Disease

About this section

MalaCards organs/tissues related to Sezary's Disease:

42
T Cells, Skin, Bone Marrow, Lymph Node, B Cells, Kidney, Colon
Sources

Publications for Sezary's Disease

About this section

Articles related to Sezary's Disease:

(show top 50) (show all 837)
# Title Authors Year
1
Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome. ( 30180750 )
2019
2
Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument. ( 30617041 )
2019
3
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection. ( 31046767 )
2019
4
Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review. ( 30525754 )
2019
5
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. ( 31049926 )
2019
6
Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. ( 30298903 )
2019
7
Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. ( 30937886 )
2019
8
Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome. ( 31045236 )
2019
9
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. ( 29947731 )
2019
10
Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients. ( 30176169 )
2019
11
Mycosis Fungoides and Sézary Syndrome: An Update. ( 30497668 )
2019
12
Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. ( 30596221 )
2019
13
Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS). ( 30691274 )
2019
14
Epidemiology and prognostic factors for mycosis fungoides and Sézary syndrome in a multi-ethnic Asian cohort: A 12-year review. ( 30801779 )
2019
15
Sézary syndrome in an anti-human T-cell lymphotropic virus type 1 seropositive carrier. ( 29952024 )
2019
16
Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab. ( 30328116 )
2019
17
Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome. ( 30356161 )
2019
18
Sézary syndrome without erythroderma: A case report and review of published work. ( 30379353 )
2019
19
Sézary Syndrome, recent biomarkers and new drugs. ( 30525758 )
2019
20
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. ( 30637815 )
2019
21
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome. ( 30638415 )
2019
22
Rapid progression of immune dysregulation in an HIV-infected patient with Sézary syndrome. ( 30710903 )
2019
23
Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients. ( 30798854 )
2019
24
Nail Changes in Sézary Syndrome: A Single-Center Study and Review of the Literature. ( 30917680 )
2019
25
Targeting CD47 in Sézary syndrome with SIRPαFc. ( 30962222 )
2019
26
Loss of β-arrestin-2 gene and possible functional consequences on Sezary Syndrome. ( 31106661 )
2019
27
Increased interleukin-36γ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sézary syndrome. ( 29314201 )
2018
28
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. ( 29800117 )
2018
29
Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. ( 30017383 )
2018
30
Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. ( 30098016 )
2018
31
Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome. ( 30213403 )
2018
32
Infections in mycosis fungoides and Sézary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done? ( 30508233 )
2018
33
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome. ( 28925057 )
2018
34
The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. ( 29152728 )
2018
35
Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. ( 29204699 )
2018
36
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. ( 29205518 )
2018
37
Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. ( 29308723 )
2018
38
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. ( 29477101 )
2018
39
The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. ( 29543675 )
2018
40
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. ( 29572582 )
2018
41
Serum Soluble CD48 Levels as a Prognostic Marker in Mycosis Fungoides and Sézary Syndrome. ( 29605670 )
2018
42
Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. ( 28533196 )
2018
43
Sézary syndrome with T/NK phenotype: A variant phenotype or a distinct clinical entity? ( 27145066 )
2018
44
Different genetic alteration of A20 in a Sézary syndrome case with Vα2-Jα22 T cell clone. ( 28296250 )
2018
45
Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody. ( 29327377 )
2018
46
SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome. ( 29334836 )
2018
47
Chronic activation profile of circulating CD8+ T cells in Sézary syndrome. ( 29423061 )
2018
48
Is HERV-K and HERV-W expression regulated by mir-155 in Sézary syndrome? ( 29582620 )
2018
49
Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment. ( 29719016 )
2018
50
Paraneoplastic arthritis in a patient with Sézary syndrome. ( 29726614 )
2018
Sources

Variations for Sezary's Disease

About this section

ClinVar genetic disease variations for Sezary's Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.428delT (p.Phe143Serfs) deletion Pathogenic rs587776632 GRCh38 Chromosome 1, 85267901: 85267901
2 BCL10 NM_003921.4(BCL10): c.428delT (p.Phe143Serfs) deletion Pathogenic rs587776632 GRCh37 Chromosome 1, 85733584: 85733584

Cosmic variations for Sezary's Disease:

9 (show top 50) (show all 93)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5574244 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2668A>C p.T890P 10:31523999-31523999 0
2 COSM5574236 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.517C>T p.P173S 10:31510708-31510708 0
3 COSM5574238 ZEB1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.752A>G p.Y251C 10:31514670-31514670 0
4 COSM44854 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.655C>A p.P219T 17:7674876-7674876 0
5 COSM44036 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.296C>T p.S99F 17:7676073-7676073 0
6 COSM44312 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.511G>A p.E171K 17:7675101-7675101 0
7 COSM45449 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.592G>C p.E198Q 17:7674939-7674939 0
8 COSM45796 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.623A>G p.D208G 17:7674908-7674908 0
9 COSM10768 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.535C>T p.H179Y 17:7675077-7675077 0
10 COSM11073 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024C>T p.R342* 17:7670685-7670685 0
11 COSM11166 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.406C>T p.Q136* 17:7675206-7675206 0
12 COSM5574229 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1918C>T p.Q640* 4:105235860-105235860 0
13 COSM42016 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4393C>T p.R1465* 4:105272774-105272774 0
14 COSM5574231 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.521C>A p.P174H 4:105234463-105234463 0
15 COSM100075 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4193T>C p.L1398P 4:105272574-105272574 0
16 COSM110772 TET2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4474G>T p.E1492* 4:105272855-105272855 0
17 COSM1716590 STAT5B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1924A>C p.N642H 17:42207711-42207711 0
18 COSM1717514 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1492A>G p.I498V 17:42324819-42324819 0
19 COSM1155743 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1919A>T p.Y640F 17:42322464-42322464 0
20 COSM5574219 SETD1A haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1211G>A p.R404H 16:30964953-30964953 0
21 COSM5104 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.392C>T p.T131I 10:87933151-87933151 0
22 COSM5159 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.733C>T p.Q245* 10:87957951-87957951 0
23 COSM23568 PTEN haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.919G>A p.E307K 10:87961011-87961011 0
24 COSM3734685 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1034C>T p.S345F 20:41163944-41163944 0
25 COSM5049787 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1025A>G p.D342G 20:41163935-41163935 0
26 COSM5049788 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1024G>A p.D342N 20:41163934-41163934 0
27 COSM3405078 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3487G>A p.E1163K 20:41173744-41173744 0
28 COSM3734686 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1559C>T p.S520F 20:41165499-41165499 0
29 COSM5574251 PLCG1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3473G>A p.R1158H 20:41173730-41173730 0
30 COSM5613080 PIK3CA haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1609C>T p.R537* 3:179218279-179218279 0
31 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.181C>A p.Q61K 1:114713909-114713909 0
32 COSM4591233 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.534G>C p.K178N 17:16165063-16165063 0
33 COSM126825 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2125C>T p.Q709* 17:16108843-16108843 0
34 COSM5574213 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3360G>C p.E1120D 17:16080448-16080448 0
35 COSM5574204 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6038C>T p.P2013L 17:16058037-16058037 0
36 COSM5574211 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.6322C>T p.Q2108* 17:16057584-16057584 0
37 COSM5574208 NCOR1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.76C>A p.Q26K 17:16194494-16194494 0
38 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.38G>A p.G13D 12:25245347-25245347 0
39 COSM5574196 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.11845C>T p.Q3949* 12:49032050-49032050 0
40 COSM5574193 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.4475G>C p.S1492T 12:49043902-49043902 0
41 COSM30358 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.7495G>A p.D2499N 12:49039283-49039283 0
42 COSM5574203 KMT2D haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.5923C>G p.L1975V 12:49041037-49041037 0
43 COSM5574250 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.3067T>C p.Y1023H 19:17830532-17830532 0
44 COSM34214 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1715C>T p.A572V 19:17837200-17837200 0
45 COSM51374 JAK3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1533G>A p.M511I 19:17838299-17838299 0
46 COSM3734693 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1975C>T p.R659C 1:64846661-64846661 0
47 COSM5574248 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2128C>G p.L710V 1:64844877-64844877 0
48 COSM2239136 JAK1 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.1961A>T p.Y654F 1:64846675-64846675 0
49 COSM7341028 FAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.710C>A p.A237D 10:89014152-89014152 0
50 COSM5574188 DNMT3B haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,mycosis fungoides-Sezary syndrome c.2292G>T p.R764S 20:32805398-32805398 0

Copy number variations for Sezary's Disease from CNVD:

7 (show top 50) (show all 353)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 38537 10 103280000 105830000 Deletion ACTR1A Sezary syndrome
2 38538 10 103280000 105830000 Deletion ARL3 Sezary syndrome
3 38539 10 103280000 105830000 Deletion BTRC Sezary syndrome
4 38540 10 103280000 105830000 Deletion COL17A1 Sezary syndrome
5 38541 10 103280000 105830000 Deletion CYP17A1 Sezary syndrome
6 38542 10 103280000 105830000 Deletion FGF8 Sezary syndrome
7 38543 10 103280000 105830000 Deletion LDB1 Sezary syndrome
8 38544 10 103280000 105830000 Deletion MGEA5 Sezary syndrome
9 38545 10 103280000 105830000 Deletion NEURL Sezary syndrome
10 38546 10 103280000 105830000 Deletion NFKB2 Sezary syndrome
11 38547 10 103280000 105830000 Deletion NT5C2 Sezary syndrome
12 38548 10 103280000 105830000 Deletion PCGF6 Sezary syndrome
13 38549 10 103280000 105830000 Deletion PDCD11 Sezary syndrome
14 38550 10 103280000 105830000 Deletion POLL Sezary syndrome
15 38551 10 103280000 105830000 Deletion PSD Sezary syndrome
16 38552 10 103280000 105830000 Deletion SH3PXD2A Sezary syndrome
17 38553 10 103280000 105830000 Deletion SLK Sezary syndrome
18 38554 10 103280000 105830000 Deletion SUFU Sezary syndrome
19 38555 10 103280000 105830000 Deletion TLX1 Sezary syndrome
20 38556 10 103280000 105830000 Deletion TRIM8 Sezary syndrome
21 39119 10 110240000 112960000 Deletion ADD3 Sezary syndrome
22 39120 10 110240000 112960000 Deletion DUSP5 Sezary syndrome
23 39121 10 110240000 112960000 Deletion MXI1 Sezary syndrome
24 39122 10 110240000 112960000 Deletion PDCD4 Sezary syndrome
25 39123 10 110240000 112960000 Deletion SMC3 Sezary syndrome
26 39709 10 118690000 123210000 Deletion BAG3 Sezary syndrome
27 39710 10 118690000 123210000 Deletion BRWD2 Sezary syndrome
28 39711 10 118690000 123210000 Deletion CASC2 Sezary syndrome
29 39712 10 118690000 123210000 Deletion EIF3S10 Sezary syndrome
30 39713 10 118690000 123210000 Deletion EMX2 Sezary syndrome
31 39714 10 118690000 123210000 Deletion FGFR2 Sezary syndrome
32 39715 10 118690000 123210000 Deletion GFRA1 Sezary syndrome
33 39716 10 118690000 123210000 Deletion HSPA12A Sezary syndrome
34 39717 10 118690000 123210000 Deletion INPP5F Sezary syndrome
35 39718 10 118690000 123210000 Deletion NANOS1 Sezary syndrome
36 39719 10 118690000 123210000 Deletion PRDX3 Sezary syndrome
37 39720 10 118690000 123210000 Deletion PRLHR Sezary syndrome
38 39721 10 118690000 123210000 Deletion RGS10 Sezary syndrome
39 39722 10 118690000 123210000 Deletion TIAL1 Sezary syndrome
40 40284 10 126610000 131820000 Deletion ADAM12 Sezary syndrome
41 40285 10 126610000 131820000 Deletion BCCIP Sezary syndrome
42 40286 10 126610000 131820000 Deletion CTBP2 Sezary syndrome
43 40287 10 126610000 131820000 Deletion DHX32 Sezary syndrome
44 40288 10 126610000 131820000 Deletion DOCK1 Sezary syndrome
45 40289 10 126610000 131820000 Deletion MGMT Sezary syndrome
46 40290 10 126610000 131820000 Deletion MKI67 Sezary syndrome
47 40291 10 126610000 131820000 Deletion MMP21 Sezary syndrome
48 40292 10 126610000 131820000 Deletion PTPRE Sezary syndrome
49 40293 10 126610000 131820000 Deletion ZRANB1 Sezary syndrome
50 42175 10 29840000 33170000 Deletion ARHGAP12 Sezary syndrome
Sources

Expression for Sezary's Disease

About this section
Search GEO for disease gene expression data for Sezary's Disease.
Sources

Pathways for Sezary's Disease

About this section

Pathways related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 BCL10 CD28 CTLA4 IFNG IFNGR2 IL2
2
PEDF Induced Signaling 65
Show member pathways
 13.68 CCR10 CD28 IFNG IFNGR2 IL2 IL2RA
3
TGF-Beta Pathway 65
Show member pathways
 13.55 IFNG IFNGR2 IL2 IL2RA IL4 IL5
4
Akt Signaling 65
Show member pathways
 13.41 CCR10 CD28 IL2 IL2RA IL4 IL5
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.36 IFNG IFNGR2 IL2 IL2RA IL4 IL5
6
PAK Pathway 65
Show member pathways
 13.3 CCR10 CD28 IL2 IL2RA IL4 IL5
7
IL-2 Pathway 65
Show member pathways
 13.21 BCL10 IFNG IFNGR2 IL2 IL2RA IL4
8
Pathways in cancer 38
12.88 IFNG IFNGR2 IL2 IL2RA IL4 IL5
9
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.76 IL2 IL2RA IL4 IL7 TNFRSF1B
10
Immune response NFAT in immune response 23
Show member pathways
 12.64 BCL10 CD28 IFNG IFNGR2 IL2 IL2RA
11
T cell receptor signaling pathway 38
Show member pathways
 12.6 BCL10 CD28 CTLA4 IFNG IL2 IL4
12
Th17 cell differentiation 38
Show member pathways
 12.56 CD28 IFNG IFNGR2 IL2 IL2RA IL4
13
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.52 IFNG IFNGR2 IL2 IL4 KIR3DL2
14
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.49 IFNG IFNGR2 IL2 IL2RA IL4 IL5
15
NF-kappaB Signaling 4
12.49 BCL10 CD28 CTLA4 IFNG IL2 IL2RA
16
ICos-ICosL Pathway in T-Helper Cell 65
Show member pathways
 12.41 BCL10 CD28 CTLA4 IL2 IL2RA
17
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.27 IFNG IL2 IL2RA IL4 IL5
18
Allograft rejection 38 1
Show member pathways
 12.18 BCL10 CCR10 CD28 CTLA4 IFNG IFNGR2
19
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.15 IFNG IFNGR2 IL2 IL2RA IL4 IL5
20
Th1 Differentiation Pathway 66
Show member pathways
 12.11 CD28 IFNG IFNGR2 IL2 STAT4
21
IL12-mediated signaling events 1
Show member pathways
 12.08 IFNG IL2 IL2RA IL4 STAT4 TRB
22
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.01 CD28 IFNG IL2 IL2RA IL4 IL5
23
Jak-Stat Signaling Pathway (sino) 68
11.93 IFNG IFNGR2 IL2 IL2RA STAT4
24
Hematopoietic cell lineage 38
11.91 IL2RA IL4 IL5 IL7
25
Innate Lymphoid Cell Differentiation Pathways 66
11.89 IFNG IL2 IL2RA IL4 IL5 IL7
26
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.85 CTLA4 IFNG IL2 IL2RA IL4 IL5
27
Glucocorticoid receptor regulatory network 1
11.83 IFNG IL2 IL4 IL5
28
Rheumatoid arthritis 38
11.82 CD28 CTLA4 IFNG
29
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.71 IFNG IL2 IL4
30
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.69 IFNG IL2 IL2RA STAT4
31
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.68 IL2 IL2RA IL4
32
Transcription_NF-kB signaling pathway 23
11.58 CD28 TNFRSF1B TRB
33
Cellular Transformation by HTLV1 65
Show member pathways
 11.54 IFNG IFNGR2 TNFRSF1B
34
Development and heterogeneity of the ILC family 1
11.39 IFNG IL4 IL5 IL7
35
T-Cell Receptor and Co-stimulatory Signaling 1
11.37 CD28 CTLA4 IL2 TRB
36
Th2 Differentiation Pathway 66
11.36 CD28 IFNG IL2 IL2RA IL4 IL5
37
IL12 signaling mediated by STAT4 1
11.32 CD28 IFNG IL2 IL2RA STAT4
38
Immune response_IL-12 signaling pathway 23
Show member pathways
 11.28 IFNG IL2RA STAT4
39
OX40 Pathway 65
11.28 IFNG IL2 IL4 IL5
40
G-protein signaling_RhoB regulation pathway 23
11.21 IL2 IL4 IL5 IL7
41
Cytokines and Inflammatory Response 1
11.2 IFNG IL2 IL4 IL5 IL7 TRB
42
Inflammatory Response Pathway 1
11.02 CD28 IFNG IL2 IL2RA IL4 IL5
Sources

GO Terms for Sezary's Disease

About this section

Cellular components related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex involved in cell adhesion GO:0098636 8.62 CD28 CTLA4

Biological processes related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 DPP4 IFNG IL2 IL5 IL7
2 regulation of signaling receptor activity GO:0010469 9.93 IFNG IL2 IL4 IL5 IL7
3 adaptive immune response GO:0002250 9.9 BCL10 CTLA4 IFNG IL2
4 cell surface receptor signaling pathway GO:0007166 9.83 CD28 IFNG IFNGR2 IL2RA TNFRSF1B
5 negative regulation of inflammatory response GO:0050728 9.78 IL2 IL2RA TNFRSF1B
6 cytokine-mediated signaling pathway GO:0019221 9.76 IFNGR2 IL2 IL2RA IL4 IL5 IL7
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 IFNG IL2 IL4
8 positive regulation of T cell proliferation GO:0042102 9.71 CD28 IL2 IL2RA IL4
9 humoral immune response GO:0006959 9.7 CD28 IFNG IL7
10 T cell costimulation GO:0031295 9.67 CD28 CTLA4 DPP4
11 T cell activation GO:0042110 9.65 CD28 DPP4 IL4
12 positive regulation of B cell proliferation GO:0030890 9.62 IL2 IL4 IL5 IL7
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG TNFRSF1B
14 negative regulation of immune response GO:0050777 9.58 CTLA4 IL2RA
15 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.58 IFNG IFNGR2
16 positive regulation of immunoglobulin secretion GO:0051024 9.57 IL2 IL5
17 interleukin-2-mediated signaling pathway GO:0038110 9.56 IL2 IL2RA
18 positive regulation of T cell differentiation GO:0045582 9.56 IL2 IL2RA IL4 IL7
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.54 CD28 IL2 IL4
20 negative regulation of lymphocyte proliferation GO:0050672 9.51 IL2 IL2RA
21 regulation of T cell homeostatic proliferation GO:0046013 9.46 IL2 IL2RA
22 regulation of regulatory T cell differentiation GO:0045589 9.35 CD28 CTLA4 IFNG IL2 IL2RA
23 immune response GO:0006955 9.32 CCR10 CD28 CTLA4 IFNG IL2 IL2RA

Molecular functions related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 BCL10 CD28 DPP4
2 growth factor activity GO:0008083 9.26 IL2 IL4 IL5 IL7
3 kinase activator activity GO:0019209 9.16 BCL10 IL2
4 cytokine activity GO:0005125 9.02 IFNG IL2 IL4 IL5 IL7
Sources

Sources for Sezary's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb